Thrombosis complicating high dose intravenous immunoglobulin: Report of three cases and review of the literature

European Journal of Neurology

Volumn 10, Issue 4, 2003, Pages 367-372

  Zaidan, Radwan ^a,c   Al Moallem, M ^a   Wani, B A ^b   Shameena, A R ^a   Al Tahan, A R ^a   Daif, A K ^a   Al Rajeh, S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Riyadh Medical Complex   (Saudi Arabia)

^c KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Complications; CVA; Intravenous immunoglobulin (IVIG); MI; Therapy; Thrombosis

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADULT; AGED; ANAMNESIS; BRAIN INFARCTION; CASE REPORT; CLINICAL FEATURE; DRUG MEGADOSE; FEMALE; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HUMAN; IMMUNOTHERAPY; MALE; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; REVIEW; THROMBOSIS; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; ISCHEMIA; METHODOLOGY; MIDDLE AGED;

AGED; AGED, 80 AND OVER; CEREBRAL INFARCTION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISCHEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; THROMBOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0042786902     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2003.00542.x     Document Type: Review

References (29)

1. Alliot C, Barrios M, Tabuteau S, Desablens B (2000). Autoimmune cytopenias associated with malignancies and successfully treated with intravenous immune globulins: about two cases. Therapie 55:371-374.
2. Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D (2001). Pulmonary embolism after intravenous immunoglobulin. J R Soc Med 94:187-188.
3. ASHP (1992). Therapeutic guidelines for intravenous immunoglobulin. Clin Pharmacol 11:111-116.
4. Berkman SA, Lee ML, Gale RP (1990). Clinical use of intravenous immunoglobulins. Ann Intern Med 112:278-292.
5. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH (1996). Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 19:388-391.
6. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP (1996). Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47:674-677.
7. Dalakas MC (1994). High-dose intravenous immungolobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44:223-226.
8. Dalakas MC (1997). Intravenous immunoglobulin therapy for neurologiocal diseases. Ann Intern Med 126:721-730.
9. ElKayam O, Paran D, Milo R et al (2000). Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 59:77-80.
10. Fisman DN, Smilovitch M (1997). Intravenous immunoglobulins, blood viscosity and myocardial infarction. Can J Cardiol 13:775-777.
11. Go RS, Call TG (2000). Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75:83-85.
12. Happlea SS, Farrar JT, Gibson GA, Laskin M, Pizzi LT, Asbury AK (1997). Thromboembolic events associated with intravenous immunoglobulin therapy (Abstract). Neurology 48:A54.
13. Harkness KA, Goulding P (2000). Central retinal vein occlusion complicating treatment with intravenous immunoglobulin. Eye 14:662-663.
14. Hughes R, Bensa S, Willison H et al. (2001). Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Randomized controlled trial of intravenous immuno-globulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195-201.
15. Oh KT, Boldt HC, Danis RP (1997). Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 124:416-418.
16. Paolini R, Fabris F, Cella G (2000). Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol 65:177-178.
17. Reinhart WH, Berchtold PE (1992). Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339:662-664.
18. Ropper AH, Adelman L (1992). Early Guillain-Barré syndrome without inflammation. Arch Neurol 49:979-981.
19. Rosenbaum JT (1997). Myocardial infarction as a complication of immunoglobulin therapy. Arthritis Rheum 40:1732-1733.
20. ++ movements and nitric oxide production in endothelial cells. J Biol Chem 271:26473-26476.
21. Silbert PL, Knezevic WV, Bridge DT (1992). Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 42:257-258.
22. Steg RE, Leftkowitz DM (1994). Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 44:1180-1181.
23. Thornton CA, Ballow M (1993). Safety of intravenous immunoglobulin [editorial]. Arch Neurol 50:135-136.
24. Turner B, Willis AJ (2000). Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 68:790-791.
25. Van der Meché FG, Schmilz PI (1992). The Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 326:1123-1129.
26. Van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M (1990). High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209-212.
27. Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R (1996). Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin. Neurology 46:250-251.
28. Wolberg AS, Kon RH, Monroe DM, Hoffman M (2000). Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 65:30-34.
29. Woodruff RK, Grigg AP, Firkin FC, Smith IL (1986). Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patient. Lancet 2:217-218.